Clarus’ Oral Testosterone’s Perceived Advantage Becomes Downfall At FDA Panel
This article was originally published in The Pink Sheet Daily
Oral dosing is “double-edge sword” as unique concerns with Rextoro’s formulation leads to negative advisory committee vote for the testosterone replacement treatment despite panelists’ desire for an oral option.
You may also be interested in...
The latest drug development news and highlights from our US FDA Performance Tracker.
Jatenzo clears US FDA 15 months after second negative advisory committee review.
Second go-round for oral testosterone could have marked new boundary on how far FDA is willing to go in approving new entrants to a market with widespread historic off-label use and CV risks.